Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
…, M van Mackelenbergh, P Sinn, C Schem… - The lancet …, 2018 - thelancet.com
Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant
chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, …
chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, …
[PDF][PDF] Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and …
…, BM Pfitzner, C Salat, S Loi, WD Schmitt, C Schem… - J Clin oncol, 2015 - academia.edu
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (…
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (…
Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto …
…, S Paepke, B Gerber, S Kümmel, C Schem… - JAMA …, 2017 - jamanetwork.com
Importance The GeparSixto trial provided evidence that the addition of neoadjuvant
carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases …
carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases …
Prediction of ovulation by urinary hormone measurements with the home use ClearPlan® Fertility Monitor: comparison with transvaginal ultrasound scans and serum …
…, J Kuhlage, C Gaβner, B Sonntag, C Schem… - Human …, 2000 - academic.oup.com
The timing of sexual intercourse in relation to ovulation strongly influences the chance of
conception. Daily serum LH measurements or transvaginal ultrasonography are not practical to …
conception. Daily serum LH measurements or transvaginal ultrasonography are not practical to …
[HTML][HTML] Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in …
…, S Wu, M van Mackelenbergh, V Müller, C Schem… - Annals of …, 2020 - Elsevier
Background The predictive value of tumor mutational burden (TMB), alone or in combination
with an immune gene expression profile (GEP), for response to neoadjuvant therapy in …
with an immune gene expression profile (GEP), for response to neoadjuvant therapy in …
[HTML][HTML] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients …
Background The predictive value of PIK3CA mutations in HER2 positive (HER2+) breast
cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the …
cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the …
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a …
…, M De Laurentiis, JY Pierga, KH Jung, C Schem… - The Lancet …, 2021 - thelancet.com
Background A subcutaneous formulation of pertuzumab and trastuzumab with recombinant
human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, …
human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, …
NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69–GeparSepto
…, B Aktas, C Denkert, C Schem… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)–paclitaxel
significantly improves the pathologic complete remission rate compared with …
significantly improves the pathologic complete remission rate compared with …
[HTML][HTML] Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the …
…, K Weber, PA Fasching, T Karn, F Marmé, C Schem… - BMC medicine, 2018 - Springer
Background The focus of this study is to identify particular microRNA (miRNA) signatures in
exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-…
exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-…
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project …
…, M Untch, K Schwedler, K Lübbe, C Schem… - Breast cancer research …, 2014 - Springer
Trastuzumab and lapatinib are established treatments for patients with HER2 (human epidermal
growth factor receptor 2)-positive breast cancer with different mechanisms of action. The …
growth factor receptor 2)-positive breast cancer with different mechanisms of action. The …